GAA-creatine in elderly
- Post by: Admin
- September 17, 2021
- No Comment
The objective of this pilot trial was to evaluate the effects of 8-week GAA-creatine supplementation versus placebo on skeletal muscle and brain creatine levels, cognitive function, functional outcomes, and safety biomarkers in men and women aged 65 years and older. Twenty-one healthy elderly individuals (age 69.6 ± 4.9 years, body mass index 27.6 ± 4.2 kg/m2; 13 women) were randomly assigned to receive a GAA-creatine mixture (2 g/day of GAA and 2 g/day of creatine) or placebo (inulin) for 8 weeks; the washout period lasted for 4 weeks to prevent any residual effects of interventions across study periods. MRS revealed that GAA-creatine significantly increased brain and muscle creatine levels in individual regions of interest from baseline to 8-week follow-up, as compared to placebo (p < 0.05). The mixture was significantly superior to placebo to improve gait speed test, 5XSST, and TUGT performance at post-administration (p < 0.01), while no differences were found between interventions for MoCA and SarQoL scores (p > 0.05). Although more studies are needed to corroborate our preliminary findings, GAA-creatine might be recognized as a nutritional intervention with the potential to tackle compromised tissue bioenergetics and functional impairments associated with aging.